05 November 2004
U.S. Company to Produce 75 Million Doses of Anthrax Vaccine
Amount bolsters national stockpiles to guard against bioterrorism
The United States is adding 75 million doses of a new anthrax vaccine to a stockpile that would protect the public in the event of a bioterror attack, according to an announcement from the U.S. Department of Health and Human Services (HHS).
The pharmaceutical company VaxGen will produce the vaccine developed by the National Institute of Allergy and Infectious Diseases and based upon earlier research conducted by the U.S. Department of Defense. The rapid development of the vaccine was enabled by Project BioShield, a program to develop countermeasures for biological, chemical radiological and nuclear threats signed into law in 2004.
The vaccine is administered as a three-dose series, so the amount going into production is enough to protect 25 million people, HHS says.
The text of the HHS press release follows.
(begin text)
U.S. Department of Health and Human Services
News Release Thursday, Nov. 4, 2004
HHS Press Office (202) 690-6343
HHS Buys New Anthrax Vaccine for Stockpile Purchase Is the First Project BioShield Contract
HHS Secretary Tommy G. Thompson announced today that HHS has awarded a contract for $877.5 million to VaxGen, Inc. to manufacture and deliver 75 million doses of a new anthrax vaccine. The full supply of the vaccine will be added to the Strategic National Stockpile and would be used to protect the public against a terrorist attack in which anthrax spores were released.
"The intentional release of anthrax spores is one of the most significant biological threats we face," Secretary Thompson said. "Acquiring a stockpile of this new anthrax vaccine is a key step toward protecting the American public against another anthrax attack."
VaxGen, based in Brisbane, Calif., will produce the new anthrax vaccine using purified recombinant protective antigen (rPA), a protein that elicits antibodies that neutralize anthrax toxins, thus providing protective immunity. Evidence from laboratory and animal research has shown that the rPA vaccine is effective in providing protection against aerosol exposure to deadly anthrax spores. In addition, clinical testing has shown the rPA vaccine to be safe in humans.
The vaccine is being evaluated as a three-dose vaccination series. Based on 75 million doses, this regimen would provide sufficient anthrax vaccine to protect 25 million people. The contract awarded today requires VaxGen to obtain licensure from the Food and Drug Administration (FDA) for using the new vaccine in both pre- and post-anthrax exposure settings. The vaccine will be made using modern manufacturing technologies, and the FDA will review the vaccine production process along with testing of individual test lots of vaccine to assure its safety and effectiveness. The contract with VaxGen is a fixed-price contract, which protects taxpayers from any cost overruns.
HHS, through its National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health, funded the development of rPA vaccine beginning in September 2002 as part of its broader effort to accelerate research into developing new medical countermeasures against potential bioterror attacks. This effort was based on more than a decade of basic rPA vaccine research carried out by the Department of Defense. This award represents the first contract under the Project BioShield, a new program intended to accelerate the development, purchase and availability of medical countermeasures for biological, chemical, radiological and nuclear threats. President Bush introduced Project BioShield in his 2003 State of the Union address. Congress passed the Project BioShield Act of 2004 and the President signed it into law on July 21, 2004.
"In an exceptionally short period of time, we have dramatically accelerated our research capacity to develop a new medical countermeasure against one of the most deadly agents of bioterrorism," said Anthony S. Fauci, M.D., director of NIAID. "Without Project BioShield, we would likely still be years away from a new anthrax vaccine and today's announcement might never have been possible."
HHS' Office of Public Health Emergency Preparedness, which oversees the research and procurement efforts under the Project BioShield program, will manage this new rPA anthrax vaccine contract. More information about Project BioShield is available at: http://www.hhs.gov/asphep/ordc/bioshield/.
Note: All HHS press releases, fact sheets and other press materials are available at http://www.hhs.gov/news. Last Revised: November 4, 2004
(end text)
(Distributed by the Bureau of International Information Programs, U.S. Department of State. Web site: http://usinfo.state.gov)
This page printed from: http://usinfo.state.gov/xarchives/display.html?p=washfile-english&y=2004&m=November&x=20041105164202cmretrop0.6097834&t=livefeeds/wf-latest.html
|
NEWSLETTER
|
| Join the GlobalSecurity.org mailing list |
|
|
|
